Home  »  Trendy Stocks   »  Petros Pharmaceuticals, Inc. (PTPI) Stock on a Boo...

Petros Pharmaceuticals, Inc. (PTPI) Stock on a Boom, Here’s Why

Petros Pharmaceuticals, Inc. (PTPI), a company engaged in the identification, acquisition, development, and commercialization of therapeutics for men’s health issues, has dipped 15.63% during the regular trading session and consequently, was trading at $2.43 when last checked. The decline could be attributed to the profit-taking factor after PTPI surged 64.57% on Wednesday and closed the day at $2.88. The increase is attributable to the company’s announcement regarding the Growth of STENDRA Tablet Sales.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report


Why PTPI Surged?

On Wednesday, PTPI announced a 476% growth year-over-year of STENDRA tablet sales as part of an exclusive digital health marketing agreement with Hims & Hers Health, Inc. Hims and her Health Inc. is a multi-speciality telehealth platform providing modern personalized health to consumers. The companies also announced the availability of additional dosages of STENDRA through the Hims & Hers platform, which ultimately would further expand the partnership.  

Closing of Direct Offering

On 19th October, PTPI announced the closing of a $5.7 million registered direct offering. The company expected gross proceeds of $5.7 million from the offering. The said that it intends to use the net proceeds from offering for expansion of its men’s health platform and working capital and general corporate purposes. Katalyst Securities LLC acted as financial advisor to Petros Pharmaceuticals for this transaction.

Q2 2021 Financial Highlights

On 17th August, PTPI reported the financial results for the second quarter of the fiscal year 2021. The quarter ended on 30th June. The net sales during the quarter were $2.5 million against $1.34 million for the same period of 2020. The total gross profit for the period was $2.1 million against $0.8 million for the same period of 2020. The selling, general and administrative expenses for the period were $4.1 million against $4.1 million for the same period of 2020. The company suffered a net loss of $2.1 million against $5.8 million for the same period of 2020. The company had cash and cash equivalents of $11 million on 30th June 2021.

Executive Commentary

Fady Boctor, PTPI President and Chief Commercial Officer, while commenting on the results said that the company has continued its strong results during the quarter. He further said that the company would continue to follow multiple tracks to achieve success in the future.

Future Outlook for PTPI

During the last month, PTPI has surged more than 50% due to business positive developments. As far as the future is concerned, stats appear to be on the side of PTPI, as the company is expected to post decent results in the coming quarters as well.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts




The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.

Receive Best Stock To Trade Before The Opening Bell



100% Free. Stop Anytime. No Spam